Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax to Present at the 2019 Cantor Global Healthcare Conference
BERKELEY, Calif. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer , Senior Vice President, Commercial, and Interim Co-President, will present at the 2019 Cantor Global Healthcare Conference on Friday, Oct. 4 , at 12 p.m. E.T.
View HTML
Toggle Summary Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on commercializing novel vaccines,
View HTML
Toggle Summary Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
EMERYVILLE, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, today announced the pricing of an underwritten public offering of 18,525,000
View HTML
Toggle Summary Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock and Warrants to Purchase Common Stock
EMERYVILLE, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other
View HTML
Toggle Summary Dynavax Announces Second Quarter 2019 Financial Results
Second quarter 2019 HEPLISAV-B® net product revenue of $8.3 million Updated net product revenue guidance of $32-$36 million for full year 2019 Conference call to be held today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation
View HTML
Toggle Summary Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on August 7
BERKELEY, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on developing novel vaccines, will report its second quarter 2019 financial results on Wednesday, August 7, 2019 , after the U.S.
View HTML
Toggle Summary Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference
BERKELEY, Calif. , June 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer , Senior Vice President, Commercial, and Interim Co-President, will present at the William Blair & Co. Annual Growth Stock Conference  on Thursday, June 6 , at
View HTML
Toggle Summary Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
Progression Free Survival (PFS) rate of 18-months in 72% of patients Clinical efficacy in patients with immunologically cold tumor at baseline The combination of SD-101 and pembrolizumab was well-tolerated, consistent with previous reports BERKELEY, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Dynavax
View HTML
Toggle Summary Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
24% overall response rate in ITT population Responses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated BERKELEY, Calif. , June 01, 2019 (GLOBE NEWSWIRE) --   Dynavax Technologies Corporation (NASDAQ: DVAX), today announced
View HTML
Toggle Summary Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
Company will explore strategic alternatives for its immuno-oncology programs Company will align its resources to focus on HEPLISAV-B commercialization Eddie Gray , CEO, to retire BERKELEY, Calif. , May 23, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced a
View HTML